KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced interim study results from Study ATX-101-11-26, a multicenter, open-label, long-term study to evaluate the safety of ATX-101, a facial injectable drug for the reduction of submental fat (SMF), which commonly presents as an unwanted double chin.
“We are pleased that the open-label study results further support the safety profile of ATX-101 for the reduction of submental fat and are consistent with our previous Phase II and the European Phase III trials,” said Patricia S. Walker, M.D., Ph.D., KYTHERA’s Chief Medical Officer. “These findings add to our robust clinical database of over 1,500 subjects treated with ATX-101 in our clinical development program for the reduction of submental fat.”
This study captured subjects who received ATX-101 (2 mg/cm 2) for up to six treatments spaced 28 days apart. The interim results included subjects who had completed Visit 9, or three months after last injection, which is the same study endpoint as the ongoing U.S. and Canadian Phase III pivotal trials. Final study results will be analyzed following completion of the study, which is 12 months after last injection.
In this study, ATX-101 was found to be well tolerated and the observed overall safety profile was consistent with findings from previous Phase II and European Phase III clinical trials. Adverse events were mostly mild to moderate, and transient. The most common adverse events were bruising, numbness, pain, swelling, redness, induration, itching and nodule formation. These adverse events were limited to the injection site and were temporally associated with treatment.Although not designed to measure efficacy, the interim results from this open-label Study 26 were also consistent with the efficacy results observed in previous studies of similar design. Mean changes from baseline in submental fat measured 12 weeks after last injection were -1.3 on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and -1.2 on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS). Additionally, 71.3% of subjects had at least a 1-grade improvement on the CR-SMFRS / PR-SMFRS composite and 14.0% had at least a 2-grade improvement on the same composite measure.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts